Completed PHASE1 INTERVENTIONAL 3-arm NCT02568098

Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects

Open-Label Study to Evaluate Safety, Tolerability, Potential Pharmacokinetic Interactions and Mosquito-Lethal Effects of Orally Administered Ivermectin, Primaquine, Dihydroartemisinin-Piperaquine, and Albendazole in Healthy Adult Subjects

Sponsor: Mahidol Oxford Tropical Medicine Research Unit

Conditions Drug Combination Healthy Pharmacokinetics

Interventions DHA-PQP IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ PQ and DHA-PQP and PQ

Updated 7 times since 2017 Last updated: May 30, 2017 Started: Oct 31, 2015 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02568098, this PHASE1 trial focuses on Drug Combination and Healthy and remains completed. Sponsored by Mahidol Oxford Tropical Medicine Research Unit, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jun 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 2 earlier versions

Feb 2017 — Jun 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mahidol Oxford Tropical Medicine Research Unit
Mahidol University
University of Oxford

Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangkok, Thailand